Functional modelling and prototyping of electronic integrated kinetic energy harvesters

The aim of developing infinite-life autonomous wireless electronics, powered by the energy of the surrounding environment, drives the research efforts in the field of Energy Harvesting. Electromagnetic and piezoelectric techniques are deemed to be the most attractive technologies for vibrational devices. In the thesis, both these technologies are investigated taking into account the entire energy conversion chain. In the context of the collaboration with the STMicroelectronics, the project of a self-powered Bluetooth step counter embedded in a training shoe has been carried out. A cylindrical device 27 × 16mm including the transducer, the interface circuit, the step-counter electronics and the protective shell, has been developed. Environmental energy extraction occurs exploiting the vibration of a permanent magnet in response to the impact of the shoe on the ground. A self-powered electrical interface performs maximum power transfer through optimal resistive load emulation and load decoupling. The device provides 360 μJ to the load, the 90% of the maximum recoverable energy. The energy requirement is four time less than the provided and the effectiveness of the proposed device is demonstrated also considering the foot-steps variability and the performance spread due to prototypes manufacturing. In the context of the collaboration with the G2Elab of Grenoble and STMicroelectronics, the project of a piezoelectric energy arvester has been carried out. With the aim of exploiting environmental vibrations, an uni-morph piezoelectric cantilever beam 60×25×0.5mm with a proof mass at the free-end has been designed. Numerical results show that electrical interfaces based on SECE and sSSHI techniques allows increasing performance up to the 125% and the 115% of that in case of STD interface. Due to the better performance in terms of harvested power and in terms of electric load decoupling, a self-powered SECE interface has been prototyped. In response to 2 m/s2 56,2 Hz sinusoidal input, experimental power recovery of 0.56mW is achieved demonstrating that the device is compliant with standard low-power electronics requirements

About the rapidity and helicity distributions of the W bosons produced at LHC

$W$ bosons are produced at LHC from a forward-backward symmetric initial state. Their decay to a charged lepton and a neutrino has a strong spin analysing power. The combination of these effects results in characteristic distributions of the pseudorapidity of the leptons decaying from $W^+$ and $W^-$ of different helicity. This observation may open the possibility to measure precisely the $W^+$ and $W^-$ rapidity distributions for the two transverse polarisation states of $W$ bosons produced at small transverse momentum.Comment: 8 pages, 5 figure

25-hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), with a clinical outcome ranging from mild to severe, including death. To date, it is unclear why some patients develop severe symptoms. Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland. In this cohort, significantly lower 25(OH)D levels (p = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years. On the basis of this preliminary observation, vitamin D supplementation might be a useful measure to reduce the risk of infection. Randomized controlled trials and large population studies should be conducted to evaluate these recommendations and to confirm our preliminary observation

Data on the stability of darunavir/cobicistat suspension after tablet manipulation

The COVID-19 outbreak is now one of the most critical crises to manage for most of the national healthcare systems in the world. In the absence of authorised pharmacological treatments, many antiretrovirals, including darunavir/cobicistat fixed combination, are used off-label in the hospital wards as life-treating medicines for COVID-19 patients. Unfortunately, for most of them, the drug products available on the market are not designed to be administered by a nasogastric tube to inpatients of intensive care units. Therefore, their manipulation, even if it can strongly affect the product quality, is necessary for the preparation of suspension to meet patients\u2019 need. In this situation, it is urgent to provide data and guidance to support hospital pharmacists and clinicians in their activity. The data in this article indicate that darunavir/cobicistat suspensions compounded by pharmacists using as active ingredient a commercially available tablet can be stable at least for one week

Seasonal variation of antiretroviral drug exposure during the year: The experience of 10 years of therapeutic drug monitoring

Although studies show an annual trend for immunosuppressive drugs, particularly during different seasons, no data are available for antiretroviral drugs exposures in different periods of the year. For this reason, the aim of this study was to investigate an association between seasonality and antiretroviral drugs plasma concentrations. Antiretroviral drugs exposures were measured with liquid chromatography validated methods. A total of 4148 human samples were analysed. Lopinavir, etravirine and maraviroc levels showed seasonal fluctuation. In detail, maraviroc and etravirine concentrations decreased further in summer than in winter. In contrast, lopinavir concentrations had an opposite trend, increasing more in summer than in winter. The etravirine efficacy cut-off value of 300 ng/mL seems to be affected by seasonality: 77.1% and 22.9% of samples achieved this therapeutic target, respectively, in winter and summer, whereas 30% in winter and 70% in summer did not reach this value. Finally, age over 50 years and summer remained in the final multivariate regression model as predictors of the etravirine efficacy cut-off. This study highlights the seasonal variation in antiretroviral drugs plasma concentrations during the year, leading to a better understanding of inter-individual variability in drug exposures. Studies are required in order to confirm these data, clarifying which aspects may be involved

Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections

Dalbavancin (DBV) is a lipoglycopeptide approved for the treatment of Gram-positive infections of the skin and skin-associated structures (ABSSSIs). Currently, its off-label use at different dosages for other infections deserves attention. This work aimed to study the clinical effectiveness and tolerability of DBV in outpatients with ABSSSIs, osteoarticular (OA), or other infections, treated with either one or two 1500 mg doses of dalbavancin, for different scheduled periods. A liquid chromatography–tandem mass spectrometry method was used to measure total DBV concentrations. PK/PD parameters and the clinical and microbiological features of this cohort were evaluated in order to investigate the best predictors of treatment success in real-life settings. Of the 76 screened patients, 41 completed the PK study. Long-term PK was comparable to previous studies and showed significant differences between genders and dosing schedules. Few adverse events were observed, and treatment success was achieved in the vast majority of patients. Failure was associated with lower PK parameters, particularly C(max). Concluding, we were able to describe DBV PK and predictors of treatment success in selected infections in this cohort, finding DBV C(max) as a possible candidate for therapeutic drug-monitoring purposes, as well as highlighting the dual-dose one-week-apart treatment as the optimal choice for OA infections

Infected pancreatic necrosis: outcomes and clinical predictors of mortality. A post hoc analysis of the MANCTRA-1 international study

: The identification of high-risk patients in the early stages of infected pancreatic necrosis (IPN) is critical, because it could help the clinicians to adopt more effective management strategies. We conducted a post hoc analysis of the MANCTRA-1 international study to assess the association between clinical risk factors and mortality among adult patients with IPN. Univariable and multivariable logistic regression models were used to identify prognostic factors of mortality. We identified 247 consecutive patients with IPN hospitalised between January 2019 and December 2020. History of uncontrolled arterial hypertension (p = 0.032; 95% CI 1.135-15.882; aOR 4.245), qSOFA (p = 0.005; 95% CI 1.359-5.879; aOR 2.828), renal failure (p = 0.022; 95% CI 1.138-5.442; aOR 2.489), and haemodynamic failure (p = 0.018; 95% CI 1.184-5.978; aOR 2.661), were identified as independent predictors of mortality in IPN patients. Cholangitis (p = 0.003; 95% CI 1.598-9.930; aOR 3.983), abdominal compartment syndrome (p = 0.032; 95% CI 1.090-6.967; aOR 2.735), and gastrointestinal/intra-abdominal bleeding (p = 0.009; 95% CI 1.286-5.712; aOR 2.710) were independently associated with the risk of mortality. Upfront open surgical necrosectomy was strongly associated with the risk of mortality (p < 0.001; 95% CI 1.912-7.442; aOR 3.772), whereas endoscopic drainage of pancreatic necrosis (p = 0.018; 95% CI 0.138-0.834; aOR 0.339) and enteral nutrition (p = 0.003; 95% CI 0.143-0.716; aOR 0.320) were found as protective factors. Organ failure, acute cholangitis, and upfront open surgical necrosectomy were the most significant predictors of mortality. Our study confirmed that, even in a subgroup of particularly ill patients such as those with IPN, upfront open surgery should be avoided as much as possible. Study protocol registered in ClinicalTrials.Gov (I.D. Number NCT04747990)